ATE370745T1 - Verbesserte polysaccharid- und glykokonjugat- vakzine - Google Patents

Verbesserte polysaccharid- und glykokonjugat- vakzine

Info

Publication number
ATE370745T1
ATE370745T1 AT03749887T AT03749887T ATE370745T1 AT E370745 T1 ATE370745 T1 AT E370745T1 AT 03749887 T AT03749887 T AT 03749887T AT 03749887 T AT03749887 T AT 03749887T AT E370745 T1 ATE370745 T1 AT E370745T1
Authority
AT
Austria
Prior art keywords
glycoconjugate vaccines
polysaccharide
improved polysaccharide
improved
polyfunctional
Prior art date
Application number
AT03749887T
Other languages
English (en)
Inventor
Massimo Porro
Original Assignee
Biosynth Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29415984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE370745(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biosynth Srl filed Critical Biosynth Srl
Application granted granted Critical
Publication of ATE370745T1 publication Critical patent/ATE370745T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Sustainable Development (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AT03749887T 2002-05-09 2003-05-07 Verbesserte polysaccharid- und glykokonjugat- vakzine ATE370745T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2002/000307 WO2003094961A1 (en) 2002-05-09 2002-05-09 Improved polysaccharide and glycoconjugate vaccines_____________

Publications (1)

Publication Number Publication Date
ATE370745T1 true ATE370745T1 (de) 2007-09-15

Family

ID=29415984

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03749887T ATE370745T1 (de) 2002-05-09 2003-05-07 Verbesserte polysaccharid- und glykokonjugat- vakzine

Country Status (8)

Country Link
US (1) US7588765B2 (de)
EP (1) EP1501542B2 (de)
AT (1) ATE370745T1 (de)
AU (2) AU2002309259A1 (de)
CA (1) CA2484279A1 (de)
DE (1) DE60315827T3 (de)
ES (1) ES2293002T5 (de)
WO (2) WO2003094961A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638602A1 (de) * 2003-06-23 2006-03-29 Baxter International Inc. Impfstoffe gegen neisseria meningitidis gruppe y, sowie deren meningokokkale kombinationen
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2425853A1 (de) 2005-04-08 2012-03-07 Wyeth LLC Multivalente Pneumokokken-Polysaccharidproteinkonjugatzusammensetzung
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
ES2375314T3 (es) 2007-02-28 2012-02-28 Lipoxen Technologies Limited Reducción de endotoxina en ácidos polisiálicos.
GB0810894D0 (en) * 2008-06-13 2008-07-23 Novartis Vaccines & Diagnostic Conjugated saccharide
CA2756170C (en) 2009-03-23 2019-04-02 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
WO2011148382A1 (en) 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
EP3177325B1 (de) 2014-08-08 2020-04-01 GlaxoSmithKline Biologicals S.A. Modifizierte wirtszellen und oligosaccharid-hybride zur verwendung in der herstellung von biokonjugaten
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3691677A4 (de) 2017-10-04 2021-07-07 Pogona, Llc Saccharid-polypeptidkonjugat-zusammensetzungen und verfahren zur verwendung davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5371186A (en) * 1991-02-11 1994-12-06 Biosynth S.R.L. Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
AU678549B2 (en) * 1992-01-16 1997-06-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
IT1287158B1 (it) * 1996-11-13 1998-08-04 Biosynth Srl Uso combinato di peptidi sintetici anti-endotossina e di anticorpi anti-endotossina per la profilassi ed il trattamento delle
US6951652B2 (en) * 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases

Also Published As

Publication number Publication date
EP1501542B1 (de) 2007-08-22
EP1501542B2 (de) 2011-11-02
EP1501542A1 (de) 2005-02-02
AU2003242535A1 (en) 2003-11-11
WO2003094959A1 (en) 2003-11-20
ES2293002T5 (es) 2012-03-20
WO2003094961A1 (en) 2003-11-20
US7588765B2 (en) 2009-09-15
AU2002309259A1 (en) 2003-11-11
CA2484279A1 (en) 2003-11-20
DE60315827T2 (de) 2008-05-15
DE60315827D1 (de) 2007-10-04
DE60315827T3 (de) 2012-04-26
ES2293002T3 (es) 2008-03-16
US20060165730A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
CY1107390T1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
ATE542829T1 (de) Impfstoff
MXPA05014016A (es) Proteinas portadoras para vacunas.
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DE60141773D1 (de) Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
GB0113798D0 (en) Antigens and vectors for vaccination
WO2007140244A3 (en) Vaccination of young animals against lawsonia intracellularis infections
DK1274853T3 (da) Materialer og fremgangsmåder, der angår immunreaktioner på fusionsproteiner
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
NO20020615L (no) Vaksine
NZ515041A (en) Nucleic acid immunization
ATE421331T1 (de) Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
EP1667634A4 (de) Anthrax-vakzine
DK1227840T3 (da) Adjuverede, genetiske vacciner
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
BR0303226A (pt) Proteìnas de aderência e penetração de haemophilus
ATE355077T1 (de) Verwendung von peptidvektoren zur verbesserung der immunantwort gegen antigene

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties